SERUM ISCHEMIA MODIFIED ALBUMIN LEVELS IN SUBCLINICAL CUSHING'S SYNDROME

Ozku F., Turkon H., ÜLKER ÇAKIR D., Eroglu M., Tutunculer F. K., Faydaci U., ...More

ACTA MEDICA MEDITERRANEA, vol.32, no.2, pp.463-467, 2016 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.19193/0393-6384_2016_2_71
  • Journal Name: ACTA MEDICA MEDITERRANEA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.463-467
  • Çanakkale Onsekiz Mart University Affiliated: Yes

Abstract

Introduction: Subclinical Cushing's syndrome (SCS) is defined as biochemical overt cortisol excess in the absence of the classical signs and symptoms of Cushing's disease. The prevalence of SCS is reported as between approximately 5% and 24% in patients with adrenal incidentalomas (AI). SCS has increased cardiovascular and metabolic risk factors, and metabolic syndrome. Recently some studies demonstrated oxidative stress enhancement in Cushing's disease. Ischemia-modified albumin (IMA) is a marker of ischemia and oxidative stress and is increased in different clinical conditions such as cardiovascular diseases and metabolic syndrome. However, it has not been investigated in the patients with SCS. We aimed to evaluate serum IMA levels in the patients with SCS.